SQUARE

e-

SQUARE

 
Healthcare online Keeping you up-to-date
VOL.  7     ISSUE:  2    February 28, 2009 Medical Services Department

SQUARE Pharmaceuticals Ltd.

EDITORIAL

Dear Doctor:

Welcome to this edition of 'e-SQUARE' . Hope you are enjoying this online healthcare bulletin.

Our current issue focused on some interesting features like

"Blood Glucose Alert !", "COPD And Depression !", "Fast Food Alert !", "CTCs & Prostate Cancer !", "Chondroitin & Arthritis !", "CT Radiation !".

In our regular feature, we have some new products information of SQUARE Pharmaceuticals Ltd. as well.

We will appreciate your feedback !

Click on to reply mode.

Yours sincerely,

 

Editorial Team

Reply Mode      : e-square@squaregroup.com

The views expressed in this publication do not necessarily reflect those of its editor or SQUARE PHARMACEUTICALS LTD.

 Blood Glucose Alert !

 Higher Blood Glucose Could Impair Thinking

In people with type 2 diabetes, higher average blood glucose levels may be linked to lower brain function, according to a new study. Researchers found that patients with higher levels of hemoglobin A1C had significantly worse results while doing cognitive tasks that tested memory, speed and the ability to manage multiple tasks at the same time. Higher A1C levels were also associated with lower scores on a test of global cognitive function. "Even a mild impairment in cognitive function is of concern for people with type 2 diabetes,” according to lead researcher of Tel-Aviv University in Israel. However, the researchers noted it's not yet clear whether higher blood sugar levels increase the risk for cognitive impairment or whether cognitive impairment decreases the body's ability to control blood sugar levels. They hope the question will be answered in the ongoing “Action to Control Cardiovascular Risk in Diabetes (ACCORD)-MIND (Memory in Diabetes)” study, which will test the theory that lowering A1C levels could improve cognitive function. Previous research found that people with diabetes are 1.5 times more likely to suffer cognitive decline and dementia than people without diabetes.

SOURCE: HealthDay News, January 2009.

Return to top

 COPD And Depression !

COPD Raises Risk Of Depression

Patients with COPD appear to have a significantly higher risk of becoming clinically depressed than healthy individuals and patients with another common chronic condition - diabetes. "The relationship between depression and COPD was described before, but what this study adds is that a temporal relationship is found. In other words, COPD did lead to a higher risk for a diagnosis of depression," according to the researcher from Radboud University Nijmegen Medical Centre, The Netherlands. "It seems that the increased risk of depression is not the result from having a chronic disease in general but is specific for COPD," the scientists noted. In their study, the research team compared the risk of an initial diagnosis of depression in 999 patients with COPD, 978 with diabetes, and 2494 matched control subjects without chronic health conditions. In total, 5.5 percent of the overall population of patients with COPD or diabetes could not be included in the study because of an existing history of depression. According to the investigators, the risk of a first diagnosis of depression was significantly higher in the COPD patients than in the control patients. Co-existing illness, they note, "is a well-established phenomenon that was found in 85 percent of the patients with COPD in this study but did not result in higher risk for depression in patients with COPD compared to healthy control subjects and diabetes mellitus patients." "Patients with COPD have a higher probability of a first episode of depression at any time...compared to patients with diabetes mellitus and control subjects," the researchers note.

SOURCE: Reuters Health, January 2009.

Return to top

 
 
 Fast Food Alert !

Hidden Phosphorus In Fast Food a Concern

People with advanced kidney disease are taught to avoid certain foods that are naturally high in the mineral phosphorus, which is difficult for their compromised kidneys to get rid of. But in a report the researchers warn that a fair amount of processed and fast food actually contains phosphorus additives, which can be just as harmful for people with advanced kidney disease. Because high blood levels of phosphorus can lead to heart disease, bone disease, and even death among patients with advanced kidney disease, these patients must avoid certain meats, dairy products, whole grains, and nuts that are naturally high in phosphorus, the researchers note in the Journal of the American Medical Association. The problem, according to the scientists at Case Western Reserve University in Cleveland, Ohio, is that it has become an increasingly common practice by food manufacturers to include phosphate salts to processed foods. These additives are used to enhance flavor and shelf life -- particularly in meats, cheeses, baked goods, and beverages -- and it is very hard for consumers to know whether or not these additives are present in products. In a study of 279 kidney disease patients who had elevated blood phosphorus levels, the researchers were able to significantly lower phosphorus levels by teaching patients to avoid foods containing phosphorus additives. In the randomized study, 145 "intervention" patients were given lists of common phosphorus-containing additives to check against food items at grocery stores and fast food menu items with high phosphorus content and healthy alternatives. The remaining 134 "control" patients received standard care. After three months, phosphorus levels declined two and a half times more in patients who were taught how to avoid phosphorus additives than in the control group. The investigators recommend mandating phosphorus content on food labels, and creating incentives for marketing low-phosphorus products to improve the health of patients with kidney disease, and the general public as well.

SOURCE: JAMA, February 2009.

Return to top

 
 
 CTCs & Prostate Cancer !

Circulating Tumor Cells Levels Could Predict Prostate Cancer Outcome

Checking for changes in the number of circulating tumor cells (CTCs) could help doctors predict advanced prostate cancer patients' survival and response to treatment, U.S. researchers report. They studied the association between CTC numbers (before and after treatment) and survival, along with other factors such as changes in levels of prostate-specific antigen (PSA) and baseline lactate dehydrogenase (LDH) in 164 prostate cancer patients starting first-line chemotherapy regimens. High values of CTC numbers and PSA levels before treatment were associated with increased risk of death. At four, eight and 12 weeks after treatment, changes in CTC numbers were strongly associated with increased risk of death, while changes in PSA were only marginally associated with increased risk of death. The findings confirm that pre-treatment CTC numbers help predict survival of prostate cancer patients starting first-line chemotherapy. CTC numbers also help monitor disease status and response to treatment, and CTC is a better predictor than PSA, the researchers said. "CTC number[s] can be used to monitor disease status and might be useful as an intermediate endpoint of survival in clinical trials," wrote study author of Memorial Sloan-Kettering Cancer Center in New York City. "Use as an intermediate or surrogate endpoint for survival could shorten the time line for drug approval," although "several prospective trials are needed to generate evidence to guide the use of biomarkers."

SOURCE: HealthDay News, February 2009.

Return to top

 
 
 Chondroitin & Arthritis !

Chondroitin Useful For Arthritis Of Knee

Long-term use of prescription-grade chondroitin sulfate for treatment of knee arthritis reduces pain and slows joint narrowing, investigators report. The Study on Osteoarthritis Progression Prevention (STOPP) involved 622 patients in Europe and the US, ages 45-80 years, with knee arthritis. On average, the patients reported moderate levels of pain when the study began. Patients were randomly assigned to 2 years of daily treatment with chondroitin or inactive "placebo." X-rays of the affected knee were taken to assess the impact of treatment. Pain relief increased with time in the chondroitin group, researchers at Cochin Hospital in Paris report. Moreover, treatment with chondroitin reduced the likelihood of joint narrowing -- indicating a loss of cartilage -- by 33 percent. Over 90 percent of the subjects reported good or very good tolerability with chondroitin, and side effects were no more likely than with placebo. The authors note that because the chondroitin used in the STOPP trial is a prescription drug, the results cannot be generalized to chondroitin products sold as dietary supplements.

SOURCE: Reuters Health, February 2009.

Return to top

 
 
 CT Radiation !

CT Scan May Give Patients High Radiation Dose

Patients are receiving the equivalent of 600 chest X-rays when they get CT scans for heart disease and not enough clinics are using known ways to reduce this exposure, researchers reported. While the potential risk of developing cancer after a cardiac CT scan is slight, at less than 1 percent, researchers in the large, international study found the radiation doses from such tests varied widely among hospitals, suggesting more can be done to minimize patients' exposure. "It does drive home the fact that, yes, those scanners do impart a radiation dose, and the doctors together with their patients really have to think about whether or not the scan is the best approach for the particular patient," according to the study co-author of the Mayo Clinic in Jacksonville, Florida. The researcher headed an American Heart Association panel that called on for more careful selection of patients who receive diagnostic tests such as CT scans to minimize the doses of ionizing radiation. So called "64-slice" CT scans, which take dozens of images in one rotation around the body, are an increasingly popular tool to diagnose coronary artery disease, particularly in patients with symptoms such as chest pain or shortness of breath. But a number of recent studies have raised alarm about the potential cancer risks from the radiation. The scientists of the Technical University, Munich, Germany studied 1,965 patients who had cardiac CT scans between February and December 2007 at 50 university and community hospitals worldwide. They found the median dose from a heart CT scan, as calculated by a measurement of absorbed radiation, differed significantly from hospital to hospital. The median radiation dose from all sites was equivalent to 600 chest X-rays, they reported in the Journal of the American Medical Association. Some variability in dosage was attributed to factors that included patient weight, absence of stable heart rhythm, the length of the scan and the type of CT system used. While strategies are available that can substantially lower radiation doses from CT scans, such as reducing voltage, some of these techniques are not being widely used, the researchers found. That could be because many clinicians may still be unfamiliar with the magnitude of radiation exposure that is received from a cardiac CT scan, they said. "The findings suggest that dose-reduction methods can be used in the majority of patients, which should serve as a wake-up call to cardiac CT laboratories that do not routinely use these methods," according to the researcher.

SOURCE: Reuters Health, February 2009.

Return to top

 
 

New Products of SQUARE Pharmaceuticals Ltd.

  Product Evit® Licap
  Generic Name Vitamin E
  Strength 400 mg
  Dosage form Liquid Capsule
  Therapeutic Category Vitamin E Plain
  Product Sulprex® Refill
Generic Name

Salbutamol + Ipratropium

Strength

100 mcg + 20 mcg/puff

Dosage form MDI
Therapeutic Category Inhaled Short acting β2 agonist + Anti-cholinergic
  Product Ziliron® - B
  Generic Name Iron (III) Hydroxide Polymaltose Complex INN, Folic Acid, Vitamin B-Complex & Zinc Sulphate Monohydrate
  Strength Iron (III) Hydroxide Polymaltose Complex INN 188 mg equivalent to elemental Iron 47 mg, Folic Acid BP 0.50 mg, Thiamine Hydrochloride BP 5 mg, Riboflavin BP 2 mg, Pyridoxine Hydrochloride BP 2 mg & Zinc Sulphate Monohydrate USP 61.80 mg
  Dosage form Timed Release Capsule
  Therapeutic Category Antianaemic

Return to top

 

Copyright © 2009 SQUARE Pharmaceuticals Ltd. All rights reserved.